Shah R, et al. – Researchers conducted a meta-analysis of 14 randomized, controlled trials (n = 164,751) to determine the role of aspirin for the primary prevention of cardiovascular diseases, especially in the context of contemporary aggressive preventive strategies. They did not identify any differences between aspirin and placebo in the risks for all-cause stroke, cardiac death, and all-cause mortality. They noted, however that the impact of aspirin on myocardial infarction risk has been significantly attenuated in the context of contemporary primary prevention guidelines, while its major bleeding and hemorrhagic stroke complications have been retained. Therefore, routine use of aspirin to primarily prevent cardiovascular events can have a net damaging impact in contemporary practice.